Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD.
Salas MQ, Prem S, Atenafu EG, Datt Law A, Lam W, Al-Shaibani Z, Loach D, Kim DDH, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A. Salas MQ, et al. Among authors: atenafu eg. Bone Marrow Transplant. 2020 Sep;55(9):1773-1783. doi: 10.1038/s41409-020-0813-9. Epub 2020 Feb 5. Bone Marrow Transplant. 2020. PMID: 32024990
Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation.
Alam N, Marras TK, Atenafu EG, Gupta V, Kuruvilla J, Lipton JH, Messner HA, Kim DD. Alam N, et al. Among authors: atenafu eg. Biol Blood Marrow Transplant. 2012 Dec;18(12):1905-10. doi: 10.1016/j.bbmt.2012.07.012. Epub 2012 Jul 23. Biol Blood Marrow Transplant. 2012. PMID: 22835425 Free article.
A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim DD, Uhm J, Lambie A, Ellis L, Lipton JH. Shanavas M, et al. Among authors: atenafu eg. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):87-92. doi: 10.1016/j.clml.2013.09.010. Epub 2013 Oct 1. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24252361
Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.
Michelis FV, Messner HA, Atenafu EG, Kim DD, Kuruvilla J, Lipton JH, Uhm J, Loach D, Gupta V. Michelis FV, et al. Among authors: atenafu eg. Biol Blood Marrow Transplant. 2014 Apr;20(4):474-9. doi: 10.1016/j.bbmt.2013.12.560. Epub 2013 Dec 15. Biol Blood Marrow Transplant. 2014. PMID: 24345422 Free article.
Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.
Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim DD, Uhm J, Lambie A, Ellis L, Lipton JH. Shanavas M, et al. Among authors: atenafu eg. Leuk Lymphoma. 2014 Oct;55(10):2398-401. doi: 10.3109/10428194.2014.882507. Epub 2014 Mar 7. Leuk Lymphoma. 2014. PMID: 24428200 No abstract available.
299 results